Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airway Basal Stem Cells in Pediatric Bronchiolitis Obliterans
NCT07239895Phase 1Recruiting
- Sponsor
- Regend Therapeutics
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Bronchiolitis Obliterans (BO), sponsored by Regend Therapeutics. Primary endpoints: Change in clinical symptoms at 24 weeks and Changes in oxygen therapy at 24 weeks. Started Nov 2025; status: recruiting.
02
Conditions
Bronchiolitis Obliterans (BO)
Beyond the preview
Go deeper on NCT07239895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239895.